Claims 1-7 (canceled)

Claim 8 (currently amended) A crystalline polymorph Form I of

~~(-) 4-[4-[4-[4-[[(2R-cis)-5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)furan-3-yl]methoxy]phenyl]-1-piperazinyl]phenyl-2,4-dihydro-2-[(S)-1-ethyl-2(S)-hydroxylpropyl]-3H-1,2,4-triazol-3-one~~

the compound represented by the formula I



and characterized by at least one of the following properties:

- a melting point range of about 164 to about 165°C wherein the melting point range is determined using USP Class Ia procedure;
- a specific rotation equal to $[a]^{25}_{D}$ = -29.4° wherein the specific rotation is determined using a concentration of 10 mg/ml in methanol;
- ~~the~~ an X-ray powder diffraction pattern substantially similar to that presented in Figure 1;
- ~~the~~ a differential scanning calorimetry thermogram substantially similar to that presented in Figure 7; ~~and~~ or
- ~~the~~ a proton NMR spectrum substantially similar to that presented in Figure 10.

Claims 9 and 10 (canceled)

Claim 11 (previously presented) A pharmaceutical composition comprising an anti-fungally effective amount of the crystalline polymorph form I of claim 8 and a pharmaceutically acceptable carrier.

Claims 12 and 13 (canceled)

Claim 14 (previously presented) A method of treating and/or preventing fungal infections in a mammal which comprises administering to said mammal an anti-fungally effective amount of the crystalline polymorph form I of claim 8.

Claim 15 (new) A crystalline polymorph Form II of the compound represented by the formula I



and characterized by an X-ray powder diffraction pattern displaying d spacing peaks at 20.05 and 13.84 +/-0.04.

Claim 16 (new) The crystalline polymorph Form II of Claim 15 further characterized by an X-ray powder diffraction pattern substantially similar to that presented in Figure 2.

Claim 17 (new) A pharmaceutical composition comprising an anti-fungally effective amount of the crystalline polymorph Form II of Claim 15 and a pharmaceutically acceptable carrier.

Claim 18 (new) A method of treating and/or preventing fungal infections in a mammal which comprises administering to said mammal an anti-fungally effective amount of the crystalline polymorph Form II of Claim 15.

Claim 19 (new) A crystalline polymorph Form III of the compound represented by the formula I



and characterized by an X-ray powder diffraction pattern displaying d spacing peaks at 28.69, 14.45, 10.59, 7.27, 6.59, 4.14, 3.58, and 3.53 +/-0.04.

Claim 20 (new) The crystalline polymorph Form III of Claim 19 further characterized by an X-ray powder diffraction pattern substantially similar to that presented in Figure 3.

Claim 21 (new) A pharmaceutical composition comprising an anti-fungally effective amount of the crystalline polymorph Form III of Claim 19 and a pharmaceutically acceptable carrier.

Claim 22 (new) A method of treating and/or preventing fungal infections in a mammal which comprises administering to said mammal an anti-fungally effective amount of the crystalline polymorph Form III of Claim 19.